OKYO Pharma Limited (LSE: OKYO) announces that 297,869,806 additional Ordinary Shares have today been admitted to listing on the standard segment of the Official List of the Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc as the result of the conversion of certain loan notes and exercise of certain warrants as detailed in the prospectus of the Company published on 5 May 2021.
Total voting rights
The total number of Ordinary Shares in issue will be 970,686,108 and this number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Shares in public hands
The percentage of shares in public hands is 44.06%.
Director Dealing
Planwise Group Limited has acquired a total of 32,014,853 Ordinary Shares as a result of the conversion of loan notes and the exercise of warrants; Panetta Partners Limited has acquired a total of 160,203,636 Ordinary Shares as a result of the conversion of loan notes and the exercise of warrants. Gabriele Cerrone, Chairman of OKYO is considered to have a beneficial interest in the Ordinary Shares held by both Panetta Partners Limited and Planwise Group Limited. Mr Cerrone’s aggregate interest in the Ordinary Shares has accordingly increased from 54.15% to 55.94%.
| 1. | Details of Persons Discharging Managerial Responsibilities “PDMR” / person closely associated with them (‘PCA’) | |
| a) | Name | Gabriele Cerrone |
| 2. | Reason for notification | |
| a) | Position / status | Non-Executive Chairman |
| b) | Initial notification / amendment | Initial notification |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | OKYO Pharma Limited |
| b) | LEI | 213800VVN5CB56Y15A05 |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument Identification code | ordinary shares of no par value GG00BD3FV870 |
| b) | Nature of the transaction | Conversion of Convertible Secured Loan Notes for new Ordinary Shares and exercise of warrants |
| c) | Price(s) and volume(s) | Price: (i)£0.004 per Conversion of Convertible Secured Loan Notes for new Ordinary Shares (ii) £0.085 per Conversion of Convertible Secured Loan Notes for new Ordinary Shares (iii)£0.004 on the exercise of warrants (iv)£0.0135 on the exercise of warrants (v)£0.0055 on the exercise of warrants Volume: (i) 39,605,760,; (ii) 4,643,333 (iii) 39,605,760 (iV) 36,363,636 (v) 72,000,000 |
| d) | Aggregated information – Aggregated volume – Price | 192,218,489 £1,045,332 |
| e) | Date of the transaction | 7 May 2021 |
| f) | Place of the transaction | Outside a trading venue |
Capitalised terms used in this announcement are as defined in the prospectus published by the Company on 5 May 2021, unless the context otherwise requires.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer Gabriele Cerrone, Non-Executive Chairman | +44 (0)20 7495 2379 |
| Optiva Securities Limited (Broker) | Robert Emmet | +44 (0)20 3981 4173 |